시프로플록사신 주사제 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Ciprofloxacin Injection Market

The future of the global ciprofloxacin injection market looks promising with opportunities in the hospital and clinic markets. The global ciprofloxacin injection market is expected to reach an estimated $872 million by 2035 from $467 million in 2027 with a CAGR of 5.6% from 2027 to 2035. The major drivers for this market are the increasing incidence of severe bacterial infections, the rising demand for intravenous antibiotic therapies, and the growing use in hospital critical care treatments.

• Lucintel forecasts that, within the type category, ciprofloxacin lactate & sodium chloride injection is expected to witness higher growth over the forecast period due to convenience of a lactated-saline combination.
• Within the application category, hospitals is expected to witness higher growth over the forecast period due to recent expansion in hospitals to manage bacterial infections.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to growing need for the treatment of infection within hospitals.

Emerging Trends in Ciprofloxacin Injection Market

Antimicrobial stewardship will see the 2025-2027 ciprofloxacin injection market shift to more controlled and conservative distribution of sterile injectable forms of the drug, for use on patient populations with proven or suspected resistant infections. Based on WHO and comparable regulatory agency perspectives, ciprofloxacin and other similar antibiotics will be evaluated against a risk-benefit framework to include the total cost of treatment. Risk will include the potential of pharmaceutical resistance.

• Antimicrobial Stewardship: Implementation of more rigorous and comprehensive stewardship of ciprofloxacin will leave supply available to treat patients with severe infections for which other antibiotics are inappropriate, and will optimize the route of administration.
• Sterile Manufacturing Resiliency: The unreliability of the supply of injectable sterile forms will result in the procurement of backup or alternative sources. Ciprofloxacin will likely retain the 2025 requirement of a 1-hour infusion.
• Price Discipline: Price competition among manufacturers will result in margin compression for suppliers, particularly small and medium enterprises.
• Digital Transformation of Hospitals: Antimicrobial orders will be integrated with other functions such as renal-dose prompts, allergies, microbiology, and stop orders, and will be done electronically. With better systems, demands will be more accurately predicted and unnecessary exposures reduced. Digital stewardship will influence the suppliers hospitals purchase from, and prioritize suppliers that standardize and alter their product presentation.
• Supplier Diversification: Public health and hospital groups will seek different sources for active pharmaceutical ingredients (APIs) and injectable products. New qualification programs will assess the source of the APIs and the resilience of the supply chain. Manufacturing capacity and locations will play a greater role in sourcing, especially if there is a supply disruption.

During the same time period, limited stewardship will favorable impact specialty areas, such as oncology, while suboptimal use of antimicrobials will continue to be addressed. Dependable suppliers that have a broad range of products will favorably impact product availability.

Recent Developments in the Ciprofloxacin Injection Market

Ciprofloxacin Injection: While Lucintel expects moderate growth in the 2025-2027 period, the focus will be on ensuring sufficient supply. During this time, we expect that certain regulations and issuance of new tenders will enhance the sterile-drug manufacturing capacity of some producers. While Lucintel believes the industry will focus on developing adequate, reliable, and punctual injectable drugs production in a given region, it will allow for a wide variation in the levels of procurement.

• Reliable Sterile Capacity: In January 2025, Fresenius Kabi announced a planned investment of more than €500 million to enhance its global pharmaceutical production of hospital injectables. Ownership of a given drug formulation will be of less importance in determining supply and win tenders of a given drug.
• Localization of Supply Chains: The U.S. FDA's Drug Shortages list for ciprofloxacin injectable products signaled to the marketplace that the drug was unavailable and encouraged procurement focus on supply. In the next several years, depending on the location of the supplier, production inventory may dictate the level of a hospital's procurement.
• Supply Diversification: In June 2025, Hikma Pharmaceuticals had over 150 injectable products. A large product offering may ease the financial burden of fulfilling regulations and inventory on a given drug, and facilitate a broader scope of supply for the same customer.
• Regulatory Scrutiny: FDA's focus in 2025 was on validation of sterile drug manufacturers' processes and remediation of lapses in control processes and policies that permit continued production. Suppliers of Ciprofloxacin Injection who have validated processes and data integrity are well-positioned to capture the remaining market share, particularly as large hospitals work to limit their exposure to quality-related interruptions.
• Contract Manufacturing Partnerships: In 2026, European hospitals entered into multi-year contracts for the supply of drugs and pharmaceuticals. With predictable and continuous income, manufacturers will have an incentive to improve their processes and accept service-level agreements. This trend, however, will also allow manufacturers to improve their supply and production planning.

The ability to manufacture reliably will offset the need for process and formulation improvement. Compliance and reliability of the manufacturing process and quality of the product will be as important as product innovation. Regulatory hurdles and inspections will cause lapses in supply, which will be of more concern to hospitals in the next five years than minor process and formulation improvements in pharmaceuticals.

Strategic Growth Opportunities in the Ciprofloxacin Injection Market

Ciprofloxacin injections are in high demand due to increasing numbers of resistant infections and inadequate supplies. Between 2024 and 2026, the demand for this drug is expected to shift to the ready-to-use format, and to create easier access in the less-developed countries. The Lucintel report has identified opportunities for drug companies to improve drug supply and reduce drug work load in the health care system.

• Ready-to-use Format: Products that are ready to use will decrease the chances of preparation errors. The FDA reported in March 2025 that there was a shortage of 10 different ciprofloxacin injection products. As supplies of ready-to-use ciprofloxacin become available, hospitals are likely to change their drug purchases to these supplies in an effort to reduce the time required by the pharmacy to prepare and to administer the drug to patients.
• Antimicrobial Stewardship: Suppliers of ciprofloxacin injections may offer advisory services to help health care professionals manage the proper and prudent use of the drug to prevent the development of microbial resistance. As of April 2025, the World Health Organization reported that bacterial resistance directly caused the death of 1,270,000 people worldwide each year.
• Supply To Less-developed Countries: Drug companies may enter into partnerships to supply these countries. In January 2025, ciprofloxacin injections supplied from India accounted for $2.25 billion of the total pharmaceutical exports for the month.
• Safer Packaging: Tamper-resistant packaging and multi-component containers are areas of differentiation in injectable packaging. In February 2025, the U.S. FDA approved a new ciprofloxacin injection by a major manufacturer. Suppliers that eliminate contamination risk and improve control over inventory will gain favor with customers.
• Outsourcing Manufacturing: Branded Generics and Hospitals can out-source production and fill/finish services for injectable products to specialized Contract Manufacturing Organizations (CMOs). The demand for these services is expected to increase due to the high level of injectable drug shortages. Safe and reliable services and a reliable supplier for secondary components and services will be in high demand.

In the short term, partnering to address manufacturing needs in high demand injectables will be prudent. Manufacturers in high-growth markets have the potential to quickly recover costs and offer competitively priced services. Stringent regulations on product stewardship will help manufacturers position injectable products in high demand.

Ciprofloxacin Injection Market Drivers and Challenges

Ciprofloxacin Injection Market trends and drivers are technology, economy, law, and clinical practice. The market is driven by the hospital outpatient setting, and innovation in antimicrobial drugs and growth in the healthcare system. Challenges to market growth are antimicrobial resistance, safety concerns, reimbursement and price constraints, and strict regulations. According to Lucintel, the market will be stagnant due to stringent regulations, particularly in developed markets, and the need for enhanced infection control practices in emerging markets.

The factors responsible for driving this market include :

• Oral Replacement Indication: Ciprofloxacin is indicated for the treatment of severe infections due to malfunctioning of the gastrointestinal tract. In 2025, the World Health Organization (WHO) issued a statement to prioritize the development and implementation of hospital-based antimicrobial stewardship programs. Injectable ciprofloxacin will continue to be prescribed for the treatment of infections in patients requiring intensive care unit (ICU) and/or surgical unit admissions in the next 3-5 years. The use of ciprofloxacin will be based on the type and sensitivity of the infecting pathogen.
• Flexibility in Intravenous and Oral Antibiotic Therapy: Ciprofloxacin Injection is a treatment for complicated urinary and respiratory infections and other conditions caused by bacteria that are sensitive to this medication. As of March 2025, the hospital guidelines published by the expert groups reflected flexibility in the choice of intravenous therapy versus oral therapy, based on the assessment of the patient's condition. During the following 3 to 5 years, this flexibility will probably be utilized in clinical practice. There are, however, some limitations to this flexibility, including the patient's gastrointestinal function and the severity of the infection. There is a growing recognition by healthcare professionals of the importance of results of cultures and sensitivities of pathogens and, consequently, an increased preference for this type of data when making decisions concerning antibiotic therapy.
• Expansion of Hospital Infrastructure and Diagnostic Capabilities: Increased construction of hospitals and emergency departments and improved laboratory diagnostics in various countries provides opportunities for the injection antibiotics industry. The focus of global health initiatives during 2025 was to increase investment in improving the diagnosis of infections, strengthening health systems and ensuring the availability of essential medicines. In the same period, improvement of health system's capacity and cold chain would improve the availability of medicines in public health facilities. Reliable and stable supply of medicines would allow producers to strengthen their position in the market.
• Advancements in Parenteral Manufacturing and Packaging Technology: Advances in pharmaceutical technology during 2024-2025 enabled producers of parenteral medicinal products to ensure a greater consistency of the final product and reduce product wastage. This trend, coupled with an improvement in the technology and machinery used in final product packaging, allows companies to achieve greater reliability of supply and ensure that their products comply with the quality standards established by health authorities. Producers which achieved the greatest levels of reliability of supply in the market would be in a favorable position to cater for increased demand for medicinal products, especially in the off-cycle months.
• Cost Advantages and Market Opportunities for Generic Ciprofloxacin: The trade name for a relatively inexpensive generic antibiotic. Newer antibiotic drugs can be expensive. Public funding authorities have been able to place strict control on expenditures of public health funding by utilizing less expensive generics. This has enabled a greater availability of the essential public health funds. There is considerable potential for ciprofloxacin to gain market share against some of the older generic antibiotics in public health care, especially in the short to medium term.

The challenges facing this market include:

• Resistance To Ciprofloxacin: The use of ciprofloxacin will be banned if alternative treatment options are available due to increasing fluoroquinolone resistance. Public health organizations will continue to monitor and report antibiotic resistance as one of the biggest threats to global public health in 2025. It is predicted that in the next three to five years, there will be increased resistance to ciprofloxacin and other antibiotics.
• Side Effects of Ciprofloxacin: In July 2025, the government continued to warn about the side effects of using ciprofloxacin. It is predicted that in the next three to five years, there will be increased monitoring and restrictions on the use of ciprofloxacin.
• Labeling of Ciprofloxacin: It is expected that in the next three to five years, restrictions on the labeling of ciprofloxacin will lead to an overall reduction in the use of injectable ciprofloxacin. Pharmaceutical companies will need to provide extensive documentation and work with regulatory agencies to provide evidence to support the safety of their products.

Ciprofloxacin is just one of hundreds of injectable medicines that will continue to gain market share due to improvement in the infrastructure and capacity of sterile medicines, especially in emerging markets. Other factors, like increasing antimicrobial resistance and bans and restrictions on the use of certain medicines, will create barriers to market growth. It is anticipated that in the next 3-5 years the emphasis for growth will be to supply higher quality and more reliable medicines as opposed to increasing market share.

List of Ciprofloxacin Injection Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies ciprofloxacin injection market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ciprofloxacin injection market companies profiled in this report include-

• Bayer
• Fresenius
• Zentiva
• Polpharma
• Pfizer

Ciprofloxacin Injection Market by Segment

The study includes a forecast for the global ciprofloxacin injection market by type, application, and region.

Ciprofloxacin Injection Market by Type [Value ($M) from 2019 to 2035]:

• Ciprofloxacin Lactate & Sodium Chloride Injection
• Ciprofloxacin & Glucose Injection

Ciprofloxacin Injection Market by Application [Value ($M) from 2019 to 2035]:

• Hospitals
• Clinics
• Others

Ciprofloxacin Injection Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Ciprofloxacin Injection Market

Ciprofloxacin injection is in a stable market situation with restrictions on supply and demand, and least of all, changes in indications. For the period 2025-2027, governments are dedicated to improving the production and/or access to essential medicines. Simultaneously, sponsor companies adjust their portfolios and focus on more profitable and/or higher value-added products. According to Lucintel, the focus of the industry becomes redefining their capacities and maintaining regulatory compliance.

• United States: The FDA and hospital pharmacies form the two pivotal sections of the sterile supply chain. Thus, factors affecting either one, impact the other. Ciprofloxacin injection is one of the several injectable medicines that the FDA's Drug Shortages list illustrate. The list reflects the agency's continuous efforts to assess the sterile supply and the challenges pertaining to it. Based on the list, we anticipate the situation to improve within the next three to five years through, among other strategies, contracting additional suppliers.
• China: The continuing efforts by the Chinese government to improve the quality of pharmaceutical manufacturing is echoed in the 2025 National Program. This is expected to lead to further improvements in the quality and efficiency of the pharmaceutical sector. Compliance to the revised regulatory requirements and industry consolidation are some of the likely trends in the Chinese pharmaceutical sector during the forecast period.
• Germany: The main development in Germany has been the implementation of the EU's Critical Medicines Alliance. As with other countries covered, the shortages policy of the EU remains the biggest driver of pharma M&A and investment activity. Antibiotics are one of the therapeutic areas where the EU seeks to build a more resilient supply chain, and by May 2025, manufacturers are required to submit plans to increase resilience to the European Commission. Local and regional producers of hospital injectables are expected to increase in the medium term.
• India: The India PLDI scheme has continued to provide support to local pharma manufacturers. A large number of India-based pharma manufacturers have significant capacity to produce injectables. Aurobindo, for example, has 22 facilities to produce injectables. With this capacity, India can be expected to supply hospital generics of ciprofloxacin and similar medications.
• Japan: Biennial changes to drug pricing in Japan, with the most recent changes taking effect in April 2025, did not positively impact suppliers of ciprofloxacin injection. Other essential medications, however, benefited from changes to the drug pricing and procurement frameworks. The same is expected to remain true in the near term.

Features of the Global Ciprofloxacin Injection Market

• Market Size Estimates: ciprofloxacin injection market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: ciprofloxacin injection market size by type, application, and region in terms of value ($B).
• Regional Analysis: ciprofloxacin injection market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the ciprofloxacin injection market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the ciprofloxacin injection market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the ciprofloxacin injection market by type (ciprofloxacin lactate & sodium chloride injection and ciprofloxacin & glucose injection), application (hospitals, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Ciprofloxacin Injection Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Ciprofloxacin Lactate & Sodium Chloride Injection : Trends and Forecast 2019 to 2035
• 4.4 Ciprofloxacin & Glucose Injection : Trends and Forecast 2019 to 2035

5. Global Ciprofloxacin Injection Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospitals : Trends and Forecast 2019 to 2035
• 5.4 Clinics : Trends and Forecast 2019 to 2035
• 5.5 Others : Trends and Forecast 2019 to 2035

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Ciprofloxacin Injection Market by Region

7. North American Ciprofloxacin Injection Market

• 7.1 Overview
• 7.2 North American Ciprofloxacin Injection Market by Type
• 7.3 North American Ciprofloxacin Injection Market by Application
• 7.4 The United States Ciprofloxacin Injection Market
• 7.5 Canadian Ciprofloxacin Injection Market
• 7.6 Mexican Ciprofloxacin Injection Market

8. European Ciprofloxacin Injection Market

• 8.1 Overview
• 8.2 European Ciprofloxacin Injection Market by Type
• 8.3 European Ciprofloxacin Injection Market by Application
• 8.4 German Ciprofloxacin Injection Market
• 8.5 French Ciprofloxacin Injection Market
• 8.6 Italian Ciprofloxacin Injection Market
• 8.7 Spanish Ciprofloxacin Injection Market
• 8.8 The United Kingdom Ciprofloxacin Injection Market

9. APAC Ciprofloxacin Injection Market

• 9.1 Overview
• 9.2 APAC Ciprofloxacin Injection Market by Type
• 9.3 APAC Ciprofloxacin Injection Market by Application
• 9.4 Chinese Ciprofloxacin Injection Market
• 9.5 Indian Ciprofloxacin Injection Market
• 9.6 Japanese Ciprofloxacin Injection Market
• 9.7 South Korean Ciprofloxacin Injection Market
• 9.8 Indonesian Ciprofloxacin Injection Market

10. ROW Ciprofloxacin Injection Market

• 10.1 Overview
• 10.2 ROW Ciprofloxacin Injection Market by Type
• 10.3 ROW Ciprofloxacin Injection Market by Application
• 10.4 Middle Eastern Ciprofloxacin Injection Market
• 10.5 South American Ciprofloxacin Injection Market
• 10.6 African Ciprofloxacin Injection Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunity by Type
  • 12.2.2 Growth Opportunity by Application
• 12.3 Emerging Trends in the Global Ciprofloxacin Injection Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis Overview
• 13.2 Bayer
  • Company Overview
  • Ciprofloxacin Injection Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Fresenius
  • Company Overview
  • Ciprofloxacin Injection Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Zentiva
  • Company Overview
  • Ciprofloxacin Injection Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Polpharma
  • Company Overview
  • Ciprofloxacin Injection Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Pfizer
  • Company Overview
  • Ciprofloxacin Injection Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Laboratorios Normon
  • Company Overview
  • Ciprofloxacin Injection Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Zydus Life
  • Company Overview
  • Ciprofloxacin Injection Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Sichuan Kelun Pharmaceutical
  • Company Overview
  • Ciprofloxacin Injection Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Shijiazhuang No.4 Pharmaceutical
  • Company Overview
  • Ciprofloxacin Injection Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Shanghai Liuhetang Biotechnology
  • Company Overview
  • Ciprofloxacin Injection Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us